Concord Biotech Sees Shift to Mildly Bullish Outlook Amid Strong Financial Performance
Concord Biotech has recently adjusted its evaluation score, reflecting a shift in technical trends. The company reported strong financial metrics, including a 20.62% average Return on Equity and a 26.51% annual growth rate in operating profit. Institutional investors have increased their stake, indicating growing confidence in its fundamentals.
Concord Biotech, a midcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation score. This revision reflects a shift in technical trends, moving from a sideways pattern to a mildly bullish outlook. The company has demonstrated notable financial metrics, including a robust average Return on Equity (ROE) of 20.62% and a commendable annual growth rate of 26.51% in operating profit. In its latest quarterly results for Q4 FY24-25, Concord Biotech reported net sales reaching Rs 429.88 crore, with a highest operating profit margin of 44.30%.
Additionally, institutional investors have shown increased confidence, raising their stake by 0.52% in the last quarter, now holding 18.51% of the company. This trend indicates a growing recognition of Concord Biotech's strong fundamentals and market position.
Despite the positive developments, the stock's valuation remains a point of consideration, with a Price to Book Value ratio of 12.1, suggesting a premium compared to historical averages.
For those interested in further insights, Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
